# A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

> **NCT04050865** · PHASE3 · COMPLETED · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 96 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Dexamethasone, 0.4mg
- **DEVICE:** Placebo plug with no drug

## Key facts

- **NCT ID:** NCT04050865
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-05
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04050865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04050865, "A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04050865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*